Peptides DB

Research-centric peptide and protocol reference hub

Best Peptides for Healing: Tissue Repair & Recovery

BPC-157, TB-500, GHK-Cu, MGF — the peptides with the strongest evidence for soft-tissue repair, tendon healing, and post-injury recovery. Ranked roundup with cycle guidance.

Published Jun 14, 20264 min read

BPC-157 and TB-500 dominate the healing-peptide research literature, with GHK-Cu as the strongest skin-and-connective-tissue addition. Newer entries (KPV for inflammation, LL-37 for antimicrobial-supported healing) round out the category. This ranking is by evidence quality for the relevant healing endpoint plus practical accessibility.

For the bare ranked list of all healing peptides by study count, see /peptides/category/healing. For the structured combination protocol, see Wolverine Stack.

Quick verdict table

Best for Evidence quality Typical cycle
BPC-157 Tendon, ligament, GI, muscle tear Strong animal; case-series human 4–6 weeks daily
TB-500 Tissue migration, wound closure Strong animal; Phase 2 dry-eye human 4–8 weeks (loading + maintenance)
GHK-Cu Skin, scar tissue, hair follicle Strong topical; modest injected 4–8 weeks injected, continuous topical
MGF Local muscle repair Animal-only; limited human Site-specific use, varies
KPV Inflammation-driven healing Limited but specific 4–6 weeks during flare
LL-37 Antimicrobial + healing Cathelicidin literature Variable

The major options

1. BPC-157

The most-cited healing peptide. Strong animal-literature base for tendon transection models, muscle laceration, ligament rupture, gastric/colonic ulcer healing.

Best for: Soft-tissue injuries, tendon and ligament recovery, GI inflammation, muscle tear.

Typical dose: 250 mcg twice daily SC, 4–6 weeks.

Side effects: Mild — occasional injection-site irritation, transient lightheadedness.

BPC-157 research profile.

2. TB-500 (Thymosin Beta-4 fragment)

The most-cited cell-migration peptide. Stronger evidence for epithelial/wound-closure indications than for tendon-specific use. Phase 2 dry-eye trial completed.

Best for: Post-surgical recovery, wound healing, epithelial-repair indications. Stacked with BPC-157 for tendon/soft-tissue work — see BPC-157 vs TB-500.

Typical dose: Loading 2–2.5 mg twice weekly × 4 weeks, then 2.5 mg weekly × 4 weeks.

TB-500 research profile.

3. GHK-Cu

Copper-peptide with the strongest cosmetic and skin-regeneration evidence. Injected use for systemic skin-and-tendon endpoints has weaker but plausible data.

Best for: Skin healing, scar tissue, hair follicle, post-procedure recovery. Often added to the BPC-157 + TB-500 healing stack for surgical-incision or skin-involvement cases.

Typical dose: Topical 1–3% serum continuous; injected 1–2 mg 2–3× weekly SC in 4–8 week cycles.

GHK-Cu research profile. Copper peptides guide.

4. MGF (Mechano Growth Factor)

IGF-1 splice variant produced locally in muscle in response to mechanical loading. Animal data on local muscle repair; very limited human evidence.

Best for: Speculative use for local muscle injury when BPC-157 isn't producing the expected effect. Not a first-line choice.

MGF research profile.

5. KPV

Anti-inflammatory tripeptide; α-MSH fragment. Used in research for inflammatory-driven healing problems — IBD, chronic skin inflammation, mast-cell-mediated issues.

Best for: Inflammation as the dominant pathology rather than tissue damage per se. Useful add-on for chronic inflammatory tendinopathy where BPC-157 alone doesn't address the inflammatory component.

Typical dose: 500 mcg SC or topical, daily, 4–6 weeks.

KPV research profile.

6. LL-37 (Human Cathelicidin)

Antimicrobial peptide with parallel wound-healing effects. Useful when an open wound has infection risk or when healing is delayed by low-grade colonization.

LL-37 research profile.

Indication-to-peptide mapping

  • Acute tendon injury (Achilles, rotator cuff, patellar): BPC-157 + optional TB-500 (the Wolverine Stack pattern).
  • Acute muscle tear: BPC-157, optional MGF for severe local injury.
  • Surgical incision or scar tissue concern: BPC-157 + GHK-Cu (topical) + optional TB-500.
  • Chronic GI inflammation: BPC-157 (oral has some animal data here).
  • Chronic inflammatory tendinopathy: BPC-157 + KPV.
  • Open wound with infection risk: Wound care + LL-37, ideally clinician-supervised.
  • Plantar fasciitis or chronic tendinopathy: BPC-157 4–6 weeks, evaluate, optionally add TB-500 if response plateaus.

Stacking principles

The Wolverine Stack (BPC-157 + TB-500) is the canonical healing stack. Adding GHK-Cu for skin/scar involvement is the common third addition.

What not to add:

  • A second GHRP-class compound (already covered by BPC-157's mechanism).
  • A second cell-migration peptide alongside TB-500 (mechanism overlap, no additive evidence).
  • High-dose NSAIDs concurrently — inflammation is part of healing; chronic NSAID use may blunt the healing-peptide effect.

What this category will and won't do

Will:

  • Accelerate healing of acute soft-tissue injuries in 60–80% of users (community data).
  • Reduce inflammatory pain in many users within 1–3 weeks.
  • Support post-surgical recovery as an adjunct.

Won't:

  • Replace structural repair when surgery is needed (a torn ACL won't reattach because of BPC-157).
  • Reverse degenerative joint disease (osteoarthritis won't reverse).
  • Heal chronic injuries that have been chronic for years in a few weeks.

Safety frame

Healing peptides have favorable acute-safety profiles. Long-term-use safety is the open question. Standard practice:

  • Cycle 4–6 weeks on, 4 weeks off.
  • Watch for injection-site reactions (rotate sites; see where to inject).
  • Stop if any red-flag patterns appear (peptide side effects).
  • Pre-surgery: some surgeons ask patients to stop research peptides 2–4 weeks before procedures. Ask.

Where to go from here